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Objective: Subclinical cytomegalovirus (CMV) viremia has been associated with other infections, prolonged
hospitalization, and mortality in select immunosuppressed populations. We examined the incidence and out
comes of subclinical CMV viremia in hospitalized patients with systemic autoimmune diseases (AD) [systemic
lupus erythematosus (SLE) or anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)] using a highly
sensitive CMV assay.
Methods: Prospectively collected samples were obtained from AD hospitalized patients at study entry with a
second sample collected 1 week later or at hospital discharge. Controls included age- and gender- matched in
patients without AD and outpatients with AD. All samples were tested in batch using the Abbott RealTime CMV
for investigational use assay (RT assay), with a LLOD (LLOQ) at 21 IU/mL (32 IU/mL).
Results: Twenty-three inpatients (10 SLE, 8 AAV, 5 controls), and 31 outpatient controls were recruited. Sub
clinical CMV viremia was found in 61% (11/18) of inpatient AD subjects, 3% (1/31) of outpatient AD subjects,
and in none of the five inpatient controls (p < 0.001). CMV viremia was associated with increased median length
of ICU stay (13 vs. 4 days, p = 0.033), hospital stay (17 vs. 9 days, p = 0.014) and increased nosocomial in
fections (7 vs. 1, p = 0.007). CMV viremia was not associated with overall severity of illness nor with diseasespecific activity or damage.
Conclusion: Over one-half of hospitalized AD patients in our cohort had detectable CMV viremia, which was
associated with increased length of hospital stay and nosocomial infections. These data suggest that further study
of the immunomodulatory effects of subclinical CMV viremia in AD is warranted.

1. Introduction
Although the clinical manifestations and outcomes of CMVassociated disease in immunosuppressed populations are wellrecognized, there is emerging evidence that subclinical reactivation of
CMV, even in the absence of clinically manifest disease, may impart
immunologic adverse effects. The negative clinical impact of subclinical
CMV is established in the solid organ transplant population, where it is
associated with infection risk, organ rejection, and mortality [1–3].

Although the majority of data regarding morbidity associated with
CMV reactivation are from the transplant and HIV/AIDS literature, small
studies suggest that patients with autoimmune diseases are vulnerable to
CMV reactivation and CMV-associated adverse outcomes. We and other
investigators have identified an increased prevalence of CMV IgM
seropositivity in AAV and hospitalized SLE patients [4,5]. Furthermore,
additional small studies found associations between prior CMV exposure
with changes in T cell subsets, increased risk of other infections, and
mortality in patients with autoimmune diseases [6–8]. We hypothesized
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that patients with AAV and SLE are also vulnerable to subclinical CMV
reactivation and associated adverse outcomes, due to both
disease-associated immune dysregulation and treatment with intensive
immunosuppressive therapy. Our study examined the prevalence of
subclinical CMV viremia in hospitalized patients with AAV and SLE
using an investigational, highly sensitive CMV assay, and examined its
association with subsequent clinical outcomes.

Table 1
Baseline patient characteristics.

Participants
Age (mean)
Female
gender
Race
Black
White
Other
Disease
AAV
SLE
Other

2. Materials and methods
Hospitalized patients meeting the American College of Rheuma
tology criteria for the diagnosis of SLE or patients fulfilling the reviewed
Chapel Hill criteria for primary AAV were prospectively enrolled
following informed consent. Disease activity and damage were assessed
using the Systemic Lupus Erythematosus Disease Activity Index (SLE
DAI) and Systemic Lupus International Collaborating Clinics-ACR
damage index (SLICC) for SLE patients, and the Birmingham Vasculitis
Activity Score (BVAS) and Vasculitis Damage Index (VDI) for AAV pa
tients. The Acute Physiology and Chronic Health Evaluation (APACHE)
II and Sequential Organ Failure Assessment (SOFA) scores were calcu
lated for patients recruited from the intensive care units. Age- and
gender-matched control patients were prospectively recruited. Samples
were collected at study entry and one week later (if still hospitalized).
Outpatient SLE and vasculitis patients were recruited at routine clinic
visits, at which time a single blood sample was collected. Approval by
the Henry Ford Hospital Institutional Review Board was obtained for
this study prior to any study procedures.

AD Inpatient N
(%)

Inpatient Control N
(%)

AD Outpatient N
(%)

18
47
12 (67%)

7
47
5 (71%)

31
49
26 (84%)

9 (50%)
8 (44%)
1 (6%)

2(29%)
5 (71%)
0

12 (39%)
14 (45%)
5 (16%)

8 (44%)
10 (56%)
0

NA
NA
NA

7 (22.5%)
22 (71%)
2 (6.5%)

diagnoses included COPD exacerbation, worsening tracheal stenosis,
lumbar radiculopathy, elective orthopedic surgical admission, and
abdominal pain.
3.1. CMV viremia
Detectable CMV viremia by the RT assay was found significantly
more often in inpatient AD patients (61%) than in inpatient controls
(0%) or outpatient AD patients (3%) (p < 0.001) (Fig. 1).
63% of AAV patients had detectable viremia, all of whom had a BVAS
score > 0, while 50% of SLE patients had detectable viremia, 60% of
whom had a SLEDAI score > 0 at study entry.
The average level of CMV viremia for AD patients at entry was 51.8
IU/mL, and at follow up was 175.3 IU/mL. All 7 inpatients with
detectable CMV viremia at baseline and a follow up sample had
increased viral load (maximum level of 394 IU/mL). CMV IgG titers, as
measured by standardized ELISA testing, were similar between controls,
AD patients, and AD patients with CMV viremia (2.90 vs. 3.01 vs. 3.75,
p = 0.54). The IgG titers for CMV tended to be higher in patients with
detectable CMV viremia than those without viremia (median 3.8 vs. 3.0,
p = 0.02) but IgG levels did not correlate with the level of CMV viremia
(p = 0.12).

2.1. Measurement of CMV viremia
Clinical whole blood samples were obtained and transported to the
research laboratory for separation into aliquots of plasma and PBMCs
within 2 hours. Plasma samples were stored at -80C until thawed for
testing. Patient plasma samples were tested in duplicate with both the
baseline and follow up sample tested in the same extraction and quan
tification procedures. CMV testing was performed using the Abbott
RealTime CMV for investigational use assay (RT assay) on the Abbott
m2000 instrument as per manufacturer recommendations. The Abbott
RT assay has a LLOD & LLOQ of 21 and 32 IU/mL that corresponds
adjusted to WHO standards to 13.5 and 20 copies/mL.

3.2. CMV viremia and disease scores
There were no statistically significant differences in the average
APACHE II (18 vs 20, p = 0.0.64) and SOFA scores (5 vs 2, p = 0.08)
between groups. CMV viremia was not significantly associated with
APACHE II scores (p = -0.327), but there was a trend toward association
with baseline SOFA scores (p = 0.056). Disease-specific activity mea
sures (SLEDAI and BVAS scores) and damage indices (SLICC and VDI
scores) were not significantly associated with CMV viremia.

2.2. Statistical analysis
All data collected were analyzed descriptively, followed by univari
ate and multivariate analyses. Continuous variables with normal dis
tributions were analyzed using means, standard deviations, Student’s ttest, Pearson correlations and ANOVA. Non-parametric analyses were
performed for all non-normally distributed continuous variables, ordinal
and categorical variables. All p values presented were nominal and
unadjusted for multiple comparisons. SPSS version 23 (IBM Corpora
tion, Armonk, New York) was used for all the analyses.

3.3. Clinical impact
Both the median (mean) length of intensive care unit (ICU) stay and
the total inpatient stay were significantly increased in patients with
detectable CMV viremia: 13 (25) vs 4 (5) ICU days, p = 0.033; 17 (35) vs
9 (10) total days, p = 0.014); median comparisons shown in Fig. 2.
Patients with CMV viremia had more hospital-acquired infections
than aviremic patients (7 vs 1, p = 0.007). Types of infections in the
viremic patients included pneumonia (3 patients), urinary tract infec
tion (3 patients), and one patient with meningitis. Although there was
no difference in total white blood cell count between groups, absolute
lymphocyte count in viremic patients was significantly lower than in
aviremic patients (p = 0.035). Patients with viremia also had signifi
cantly lower hematocrit levels (p = 0.024).
Two AD inpatients, neither of whom were receiving immunosup
pressive therapy prior to hospital admission, were treated for possible
CMV disease, both of whom had subclinical viremia at study entry. The

3. Results
Eighteen patients with AD, 7 inpatient controls, and 31 AD out
patients were prospectively recruited (Table 1).
In both inpatient and outpatient AD groups, SLE was the most
common diagnosis. There were 7 granulomatosis with polyangiitis
(GPA) and 1 microscopic polyangiitis (MPA) patient in the inpatient
AAV group, while the outpatient control group included patients with
GPA, MPA, Behcet disease, and IgG4 disease. Notably, all hospitalized
AAV patients enrolled were newly diagnosed and undergoing induction
therapy for vasculitis with high dose glucocorticoid therapy (median
dose > 60 mg/day), while all SLE patients had established disease, with
6/10 SLE patients with active disease (SLEDAI score > 0) and a median
daily steroid dose of 50 mg/day at study entry. The control patient
2
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Fig. 1. The majority of AD inpatients had detectable CMV viremia.

Fig. 2. CMV viremia is associated with increased ICU and total length of stay.

first patient was diagnosed with GPA during his hospitalization after
presenting with pulmonary-renal syndrome, and developed CMV
pneumonia, diagnosed by positive bronchioalveolar lavage viral culture,

worsening pulmonary infiltrates, diffuse alveolar hemorrhage with
hypoxia, and persistently detectable plasma CMV DNA by PCR. Despite
systemic antiviral therapy, he had persistent viremia, subsequently
3
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developed other systemic infections, and ultimately succumbed to
multiorgan failure. The second patient had known SLE and had admitted
to stopping her medication several months prior to presentation. She
was admitted with active SLE (arthritis and nephritis) and developed
meningitis, respiratory failure with pulmonary infiltrates, acute renal
failure, and pancytopenia during her hospitalization. This patient also
had CMV plasma DNA viremia detected at multiple time points by the
hospital laboratory assay, and met CMV syndrome criteria (fever, fa
tigue/malaise, hepatic aminotransferase elevation, and CMV viremia).
Ultimately, she received both systemic antiviral therapy and immuno
suppressive therapy, and made a full recovery. However, her clinical
picture was complicated by her active lupus in addition to concomitant
herpes simplex and candida infections, and without tissue substantiation
of end organ disease, could not be conclusively established to be CMV
disease.
Three AD inpatients had disease flares during the 6 months following
hospital discharge, all of whom had detectable CMV viremia during
hospitalization. There was a trend toward new need for hemodialysis at
hospital discharge in patients with CMV viremia, although it did not
reach statistical significance (4 vs. 1, p = .104).

immunosenescence (in the case of AD patients, their disease-associated
and treatment-associated immunosuppressed state) has been proposed
as the culprit, which allows CMV reactivation, promoting further im
mune impairment and a proinflammatory milieu. Finally, inflammation
has been proposed as the inciting event, which favors CMV replication
and activation, leading to adverse downstream immunologic conse
quences. All of these theories are supported by data from examining
conditions that have been associated with CMV reactivation disease
and/or viremia [13–15], but precisely how these hypothesized path
ways impact outcomes in immunocompromised patients remains un
defined. It is possible that any or all of these pathways may be important,
and all certainly appear potentially relevant in the context of AD, where
patients are frequently immunocompromised by medications, have un
derlying immune dysfunction related to their underlying disease, and
have a disease state driven by ongoing systemic inflammation.
5. Conclusions
CMV viremia is frequently found in patients with systemic AD, and
even at low levels is associated with adverse clinical outcomes. Data
from other immunocompromised cohorts support the association be
tween subclinical CMV reactivation with increased systemic inflamma
tion and decreased immune function, suggesting that CMV viremia
could potentially function to both intensify systemic inflammation
(increasing disease activity) and further impair immunologic function
(leading to higher risk of infection) in patients with AD. The precise
timing, duration, and immunologic consequences of CMV viremia in
patients with AD warrant further study, as CMV reactivation is a
potentially preventable and treatable complication of impaired host
immunity.
Author contributions: KM designed and oversaw study, obtained and
recorded subject data, aided in study analysis design, reviewed study
data, and was the primary contributor in writing the manuscript. JZ
received, processed, and stored patient specimens, and performed the
laboratory components of this study. JH recruited and consented sub
jects and recorded clinical data. SH recruited and consented subjects. JM
was involved in study design, oversaw all laboratory procedures and
proceedings, performed the data analysis for the study, and was a major
contributor in writing the manuscript. All authors read, edited and
approved the final manuscript.

4. Discussion
In our study, 61% of AD inpatients developed low level CMV viremia
during the first week of admission. Intriguingly, subclinical CMV
viremia was associated with adverse clinical outcomes including
increased length of ICU and hospital stay, rates of infections, and lower
lymphocyte and hematocrit levels.
Recent studies in other AD patients support that the association be
tween CMV viremia and adverse outcomes is more than just an
epiphenomenon. In rheumatoid arthritis, psoriasis, and inflammatory
bowel disease, CMV seropositivity or viremia has been associated with
more aggressive and refractory disease [9–11]. Additionally, data
examining reactivation rates of CMV in an AD cohort presenting with
fever demonstrated that CMV antigenemia was detected in 50% of pa
tients and was associated with increased risk of infection and death [12].
The presence of CMV viremia in the AAV group, all of whom received
high dose induction glucocorticoid therapy for newly diagnosed vascu
litis after admission to the hospital, is reminiscent of the solid organ
transplant population, in which the risk for CMV reactivation is highest
immediately post-transplant, when immunosuppressive therapy is at its
peak intensity. Similarly, viremia occurred at almost an equal frequency
in the SLE patients, all receiving 10mg of prednisone or less at home, but
receiving higher doses of glucocorticoids (median dose of 50mg/day)
after admission. These findings imply that treatment with glucocorti
coids, in combination with other factors such as the immunologic ab
errancies associated with AD, may lower the threshold for viral
reactivation.
There is a clear lack of consensus regarding the need for and
threshold for treating CMV viremia in AD. Even in the organ transplant
realm, where the adverse effects of subclinical viremia have been
conclusively established, the optimal threshold for and timing of in
terventions have not yet been unequivocally determined. Our pilot study
demonstrates adverse clinical outcomes and potential long-term detri
mental consequences of CMV viremia in AD inpatients; however, larger
prospective studies are needed to understand the associated underlying
immunologic perturbations and downstream effects, and to determine
the need, timing, duration, and nature for any preventative or thera
peutic interventions.
Lastly, the “chicken or egg” question-whether CMV viremia worsens
AD and comorbid conditions, or disease activity/illness precipitates
viral reactivation-remains unanswered. It appears that three proposed
interrelationships for CMV with inflammation/inflammaging could
readily be applied to CMV reactivation in AD patients. First, CMV has
been proposed as the villain, where the immunologic response to viral
reactivation
propagates
systemic
inflammation.
Secondly,
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